KRAS and neuroblastoma: A statistically significant survival advantage for the mice bearing ex-vivo SGSS05-NS3-treated SY5Y NB cells compared with control-treated NB cells was revealed by Kaplan–Meier survival curves (p = 0.0015) (Fig. 5B).